Lipid goal attainment in post‐acute coronary syndrome patients in China: Results from the 6‐month real‐world dyslipidemia international study II

Figures

• 

  FIGURE 1. Patient disposition in the study. ACS, acute coronary syndrome; ICF, informed consent form; LLT, lipid‐lowering therapy; NSTEMI, non‐ST elevation myocardial infarction; STEMI, ST elevation myocardial infarction; UA, unstable angina. LLT group: Patients on LLT ≥3 months; Non‐LLT group: LLT‐naive or off LLT for ≥3 months. *All enrolled patients also include 29 patients who had taken some dose of LLT during the 3 months prior to enrolment but could not be categorized in LLT or non‐LLT groups as per protocol‐specified definitions

• 

  FIGURE 2. LDL‐C goal attainment rates and distance to LDL‐C Goal. LDL‐C, low‐density lipoprotein cholesterol; LLT, lipid‐lowering therapy. Figure 2 (A) LDL‐C goal attainment rate as per pre‐admission risk classification; Figure 2 (B): LDL‐C goal attainment rate at baseline and 6‐month follow‐up; Figure 2 (C) Distance to LDL‐C Goal at baseline and 6‐month follow‐up

• 

  FIGURE 3. Lipid‐lowering therapy. ACS, acute coronary syndrome; LLT, lipid‐lowering therapy. Figure 3A LLT treatment pattern in all ACS patients at three time‐points: Admission, discharge, and 6‐month follow‐up; Figure 3B: Statin category in all ACS patients at three time‐points: Admission, discharge, and 6‐month follow‐up; Figure 3C: Atorvastatin‐equivalent daily statin dosage at four time‐points in all patients, LLT and Non‐LLT groups. Atorvastatin‐equivalent dose calculation: Atorvastatin 5 mg = simvastatin (10 mg), fluvastatin (40 mg), lovastatin (20 mg), pravastatin (20 mg), pitavastatin (1 mg); Atorvastatin 10 mg = simvastatin (20 mg), fluvastatin (80 mg), lovastatin (40 mg), pravastatin (40 mg), pitavastatin (2–4 mg), rosuvastatin (5 mg); Atorvastatin 20 mg = simvastatin (40 mg), lovastatin (80 mg), pravastatin (80 mg), rosuvastatin (10 mg); Atorvastatin 40 mg = simvastatin (80 mg), rosuvastatin (20 mg); Atorvastatin 80 mg = rosuvastatin (40 mg)